Zura Bio Limited (NASDAQ:ZURA - Get Free Report) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,860,000 shares, an increase of 118.9% from the September 15th total of 849,700 shares. Currently, 4.4% of the company's stock are short sold. Based on an average daily volume of 473,800 shares, the short-interest ratio is presently 3.9 days.
Zura Bio Stock Up 5.2 %
NASDAQ:ZURA traded up $0.20 during trading hours on Friday, reaching $4.06. 145,460 shares of the company's stock were exchanged, compared to its average volume of 323,066. The company has a 50-day moving average of $3.83 and a 200 day moving average of $3.88. Zura Bio has a 1-year low of $2.00 and a 1-year high of $6.86.
Zura Bio (NASDAQ:ZURA - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Sell-side analysts predict that Zura Bio will post -0.47 EPS for the current year.
Insider Buying and Selling at Zura Bio
In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the sale, the director now directly owns 2,085,418 shares of the company's stock, valued at approximately $8,070,567.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 22.10% of the company's stock.
Institutional Trading of Zura Bio
Several hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of Zura Bio in the 3rd quarter worth $62,000. Point72 Asset Management L.P. purchased a new position in shares of Zura Bio in the 2nd quarter valued at about $8,446,000. Forefront Analytics LLC increased its holdings in shares of Zura Bio by 22.1% in the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company's stock valued at $145,000 after purchasing an additional 7,531 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Zura Bio in the 2nd quarter valued at about $43,000. Finally, Armistice Capital LLC increased its holdings in shares of Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company's stock valued at $8,834,000 after purchasing an additional 876,000 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company's stock.
Analysts Set New Price Targets
ZURA has been the subject of several research analyst reports. Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a report on Thursday, August 15th. HC Wainwright began coverage on shares of Zura Bio in a research note on Thursday, September 5th. They set a "neutral" rating and a $5.00 price target for the company. Finally, Piper Sandler reiterated an "overweight" rating and set a $26.00 price target on shares of Zura Bio in a research note on Thursday, September 19th.
Read Our Latest Analysis on Zura Bio
About Zura Bio
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Featured Articles
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.